CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 21, 2018– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),
Otonomy Initiates Phase 3 Clinical Trial of Otividex in Ménière’s Disease
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) — Otonomy, Inc.